Invesco Ltd. Purchases 344,795 Shares of Illumina, Inc. $ILMN

Key Points

• Invesco Ltd. increased its stake in Illumina, Inc. by 61.2% during the first quarter, holding 908,534 shares valued at approximately $72.08 million.
• The stock, trading under NASDAQ:ILMN, has shown a 1-year low of $68.70 and a 1-year high of $156.66, with a market capitalization of $15.39 billion.
• Illumina reported earnings of $1.19 per share for the last quarter, exceeding analysts' expectations but experiencing a 4.8% revenue decline compared to the same period last year.

Invesco Ltd. lifted its position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 61.2% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 908,534 shares of the life sciences company's stock after acquiring an additional 344,795 shares during the quarter. Invesco Ltd. owned approximately 0.57% of Illumina worth $72,083,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Capital World Investors boosted its holdings in shares of Illumina by 408.6% during the 4th quarter. Capital World Investors now owns 18,025,301 shares of the life sciences company's stock valued at $2,408,721,000 after acquiring an additional 14,481,232 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Illumina by 3.5% during the 1st quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company's stock valued at $1,298,928,000 after acquiring an additional 558,243 shares in the last quarter. WCM Investment Management LLC boosted its holdings in shares of Illumina by 1.2% during the 1st quarter. WCM Investment Management LLC now owns 4,179,011 shares of the life sciences company's stock valued at $334,321,000 after acquiring an additional 49,156 shares in the last quarter. Brown Advisory Inc. boosted its holdings in shares of Illumina by 52.1% during the 1st quarter. Brown Advisory Inc. now owns 2,909,228 shares of the life sciences company's stock valued at $230,818,000 after acquiring an additional 996,589 shares in the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of Illumina by 26.9% during the 4th quarter. Northern Trust Corp now owns 1,652,935 shares of the life sciences company's stock valued at $220,882,000 after acquiring an additional 349,878 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Illumina Trading Down 1.5%

Shares of ILMN stock traded down $1.51 during mid-day trading on Thursday, hitting $99.29. The company's stock had a trading volume of 1,257,036 shares, compared to its average volume of 1,922,921. The company's fifty day simple moving average is $97.88 and its 200-day simple moving average is $89.28. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The company has a market cap of $15.26 billion, a PE ratio of 12.57, a P/E/G ratio of 2.27 and a beta of 1.37.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the company posted $0.36 EPS. The business's quarterly revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ILMN. Daiwa Capital Markets downgraded Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective on the stock. in a report on Tuesday, August 12th. Daiwa America downgraded Illumina from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 12th. Stephens set a $110.00 target price on Illumina and gave the stock an "overweight" rating in a report on Monday, August 4th. Citigroup downgraded Illumina from a "hold" rating to a "strong sell" rating and cut their target price for the stock from $85.00 to $80.00 in a report on Wednesday, July 9th. Finally, Guggenheim cut their target price on Illumina from $122.00 to $114.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Seven analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $124.58.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.